Novavax's Gregory Glenn, MD, talks about company's coronavirus vaccine candidate (Live 2/24)

Novavax's Gregory Glenn, MD, talks about company's coronavirus vaccine candidate (Live 2/24)

Share This Content
Gregory M. Glenn, MD, is the president of research and development at vaccine maker Novavax, whose COVID-19 vaccine candidate is the first to demonstrate clinical efficacy against the original coronavirus and both of the variants first identified in the U.K. and South Africa. If approved, the Novavax vaccine will be the first protein-based vaccine available, and the company is already working on an updated version of the vaccine to test against the new variants. Washington Post national health-care policy reporter Paige Winfield Cunningham interviews Glenn on Wednesday, Feb. 24 at 12:00pm ET.

Washington Post Live is the newsroom’s live journalism platform, featuring interviews with top-level government officials, business leaders, cultural influencers and emerging voices on the most pressing issues driving the news cycle nationally and across the globe. From one-on-one, newsmaker interviews to in-depth multi-segment programs, Washington Post Live brings The Post’s newsroom to life on stage. Subscribe to The Washington Post on YouTube: https://wapo.st/2QOdcqK

Follow us:
Twitter: https://twitter.com/washingtonpost
Instagram: https://www.instagram.com/washingtonpost/
Facebook: https://www.facebook.com/washingtonpost/

#WashingtonPostLive #Novavax